CIPROFLOXACIN TABLETS

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

Beschikbaar vanaf:

RANBAXY PHARMACEUTICALS CANADA INC.

ATC-code:

J01MA02

INN (Algemene Internationale Benaming):

CIPROFLOXACIN

Dosering:

250MG

farmaceutische vorm:

TABLET

Samenstelling:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250MG

Toedieningsweg:

ORAL

Eenheden in pakket:

100

Prescription-type:

Prescription

Therapeutisch gebied:

QUINOLONES

Product samenvatting:

Active ingredient group (AIG) number: 0123207006; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2009-08-20

Productkenmerken

_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CIPROFLOXACIN TABLETS
Ciprofloxacin Tablets USP
250 MG, 500 MG, 750 MG CIPROFLOXACIN AS CIPROFLOXACIN HYDROCHLORIDE
ANTIBACTERIAL AGENT
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, Ontario
L6T 1C1
Date of Revision:
September 16, 2019
Submission Control No: 229183
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................3
SUMMARY PRODUCT INFORMATION
...................................................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................................................3
CONTRAINDICATIONS
..............................................................................................................................7
WARNINGS AND PRECAUTIONS
............................................................................................................7
ADVERSE REACTIONS
............................................................................................................................
13
DRUG INTERACTIONS
.............................................................................................................................
17
DOSAGE AND ADMINISTRATION
.........................................................................................................
24
OVERDOSAGE
...........................................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
27
STORAGE AND STABILITY
....................................................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................................
29
PART II: SCIENTIFIC INFORMATION
...........